FORMULATION AND EVALUATION OF PRESS COATED TABLETS OF LANSOPRAZOLE by D., Prasanthi et al.
 
 




G. Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad-28, Telangana, India 
Email: prasanthidhanu@gmail.com 
, PRASHANTI S., MEGHANA G. 
Received: 16 Feb 2019, Revised and Accepted: 11 Apr 2019 
ABSTRACT 
Objective: Lansoprazole an proton pump inhibitor, degrades in acidic environment, hence protection of drug is done by coating the drug with 
enteric coating polymers. The aim and objective of the present study was to prepare enteric coated delayed release tablets of lansoprazole by using 
press coating technique.  
Methods: Core tablets were prepared by direct compression and evaluated for their physico-chemical properties. Press coated tablets were 
formulated by using different combinations of ethyl cellulose, HPMC E15 and HPMC K4M as a coating layer. Core and coated tablets were optimized 
by dissolution studies. Fourier transform infra-red spectroscopy (FTIR) and differential scanning calorimetry (DSC) studies were performed to 
know the compatibility of drug with various excipients. Surface morphology and uniformity of coat was evaluated by Scanning electron microscopy 
(SEM). Stability of optimized formulation was evaluated according to ICH guidelines. 
Results: Among the various formulations F5 containing ethyl cellulose: HPMC E15 (10:90) and F9 containing ethyl cellulose: HPMC K4M (25:75) 
were optimized based on the better drug release within 8 h. DSC studies and FTIR studies revealed compatibility of drug with excipients. Obtained 
SEM photographs of tablets showed that the surface of core tablet is uniformly coated with coat by press coating. Stability studies showed that the 
formulations were stable. 
Conclusion: As a result, delayed release press coated tablets developed in this study delivered lansoprazole in the intestine and protected the drug 
from degradation.  
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Oral route is the most oldest and convenient route for the 
administration of therapeutic agents. The advantages of tablets 
includes dose precision, least content variability, low cost, flexibility of 
dosage, cheapest to package, provides chemical, mechanical and 
microbiologic stability and requires minimal storage space 
requirements [1]. The main disadvantages include GI irritability. To 
prevent GI irritation tablets are coated [2]. Tablet coating is a common 
pharmaceutical technique of applying a thin polymer based film to a 
tablet or granule containing active pharmaceutical ingredient (API) 
[3]. Enteric coating is of choice when the drug has to remain intact in 
the stomach, but dissolve and release the contents once it reaches the 
small intestine [4]. Their prime intention is to delay the release of 
drugs which are inactivated by the stomach contents or may cause 
nausea or bleeding by irritation of gastric mucosa [5]. The drug chosen 
was lansoprazole, which is a proton pump inhibitor it irreversibly 
inhibit the gastric H+-K+, ATPase proton pump which is the final 
common pathway for acid secretion in response to all varieties of 
stimuli. Its administration is associated with high healing rate for 
duodenal ulcer and peptic oesophagitis [6]. The benzimidazoles 
derivatives, however, are susceptible to degradation in acidic and 
neutral media and to prevent the degradation of the acid labile 
substances, they must be coated. Coating protects the drug from acid 
and also modifies the drug release pattern. There is a requirement for 
development of lansoprazole delayed release tablets to protect from 
acidic media by press coating technique. Press-coating, also referred to 
as double compression coating, compression coating, or dry coating, is 
an old technique first proposed by Noyes in 1896. An industrial 
application of this technique was introduced during the period 1950–
1960 to allow the formulation of incompatible drugs [7]. Press coating 
technique does not require solvents, and achieves a greater increase in 
mass of core tablet than solvent-based methods [8]. It protects 
hygroscopic, light-sensitive, oxygen labile or acid-labile drugs. 
Additionally, compression coating has no limitation for the cores and 
hence overcomes the adhesion problem found in spraying methods 
[7]. Tablets with cylinder or special shapes can be press-coated. It is 
also possible to produce combination dosage forms, in which two 
active substances target different areas of the gastrointestinal tract [7]. 
Press coating allows the physical separation of incompatible drugs in 
the core and coat within the same dosage form [8]. Compression 
coated tablets consists of a core (fast disintegration or modified 
release) which is coated by compression with a solid barrier. This 
barrier should contain polymeric material, diluent(as a release 
modifier) and drug (for extended release) [7]. Compression coated 
tablets could be modulated to provide different release patterns 
depending on the drug distribution and with different type of 
controlling polymer used in core and coat. Based on this concept, the 
possibly obtainable modified drug releases are extended release or 
delayed release [8]. For the time controlled release system from 
compression coated tablets, the amount of the outer shell is a key 
factor for controlling the lag time [9]. Higher amount of outer coating 
added would prolong the lag time of drug release. Insufficient amount 
of polymer coat would result in absence of the lag time, since the drug 
might be released through the incomplete form of compression coat. 
The main difficulty in the manufacture of press-coated tablets is how 
to center the inner core tablet under rapid processing conditions. 
Eccentric localization may alter lag time and release profile, leading to 
the changes in drug bioavailability [10]. Reproducibility of drug 
release from press-coated tablets becomes uncertain with off center 
placement of the core tablet. Recently, the novel ENCORE™, one-step 
dry-coated tablet (OSDRC) method, pulse-echo ultrasonic approach, 
and x-ray computed tomography (CT) technique has been applied to 
solve manufacturing problems with central position deviation and 
absence of a core in the press-coated tablet [9]. In the present study, 
enteric coating polymers were used for press coating technique. 
Polymers used for coating are different combinations of ethyl cellulose 
with HPMC E15 and HPMC K4M. The amount of coating on surface of 
tablet is critical to the effectiveness of oral dosage form. 
MATERIALS AND METHODS 
Lansoprazole was obtained as gift sample from Dr. Reddy’s 
Laboratories Pvt Ltd, HPMC E15, HPMC K4M, Micro crystalline 
cellulose, Ethyl cellulose E 1415 were procured from Yarrow 
chemical products, Mumbai. Polyvinylpyrrolidone, Sodium starch 
glycolate were procured from SD fine chemicals limited, Mumbai. 
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Preparation of core tablet 
The inner core tablets were prepared by using direct compression 
method. Powder mixtures of Lansoprazole, micro crystalline 
cellulose (MCC), poly vinyl pyrrolidine (PVP), sodium starch 
glycolate (SSG) were dry blended for 20 min followed by addition of 
magnesium stearate. These mixtures were then further blended for 
10 min. 50 mg of resultant powder blend was compressed using 4.76 
mm punch to obtain core tablet [11]. Different formulations of core 




Table 1: Formulations of core tablet 
CT1  CT2  CT3  CT4  CT5  CT6  
Drug  30 mg  30 mg  30 mg  30 mg  30 mg  30 mg  
MCC  17.5 mg  17 mg  16.5 mg  16 mg  15.5 mg  18.25 mg 
PVP  1.5 mg  1.5 mg  1.5 mg  1.5 mg  1.5 mg  1.5 mg  
SSG  0.75 mg 1.25 mg  1.75 mg  2.25 mg  2.75 mg  _  
Mg stearate  0.25 mg  0.25 mg  0.25 mg  0.25 mg  0.25 mg  0.25 mg  
 
Preparation of press coated tablet 
The various formulation compositions containing ethyl cellulose and 
HPMC E15 and other formulation compositions containing ethyl 
cellulose and HPMC K4M were weighed and dry blended at about 10 
min. These are used as coating material to prepare press coated tablets 
respectively by direct compression. The optimized core tablets are press 
coated with 100 mg of mixed blend. 75 mg of coating layer material was 
weighed and transferred into 6 mm die and then core tablet was 
carefully placed manually at the center. The remaining 25 mg of barrier 
material was added into die and compressed [11]. Different coating 
combinations of core tablets are mentioned in 
 
table 2. 
Table 2: Different coating combinations of core table
COAT(mg)  
t 
F1  F2  F3  F4  F5  F6  F7 F8 F9 F10 F11 F12 F13 
Ethyl cellulose  100  75  50  25  10  5  - - 25 50 75 90 95 
HPMC E15  - 25  50  75  90  95  100 - - - - - - 
HPMC K4M  - - - - - - - 100 75 50 25 10 5 
 
Total weight of tablet-150 mg 
Evaluation of core tablet and coated tablet 
Pre compression parameters 
The powder blend for core and coated tablets was evaluated for flow 
properties and compressibility. 
Bulk density 
Bulk density was determined by pouring 15 gm (M) of sample 
through a glass funnel into 50 ml graduated cylinder. The bulk 
volume (V) 
Tapped density 
occupied by the samples were recorded [12]. Bulk 





Tapped density was determined by using Electro lab density tester, 
which consists of a graduated cylinder mounted on a mechanical 
tapping device. An accurately weighed (M) sample of powder was 
carefully added to the cylinder with the aid of a funnel [12]. 
Typically, the initial volume was noted, and the sample is then 
tapped (100 tappings) until no further reduction in volume is noted 
or the percentage of difference is not more than 2%. A sufficient 
number of taps should be employed to assure reproducibility for the 
material in question. True volume (V) was noted and tapped density 





Compressibility index and hausner ratio 
Both the compressibility index and the Hausner’s ratio were 
determined by using bulk density and the tapped density of a 
powder [12].  
compressibility index =







Angle of repose 
The angle of repose has been used to characterize the flow 
properties of solids. Angle of repose is a characteristic related to 
interparticulate friction or resistance to movement between 
particles [13]. This is the maximum angle possible between surface 
of pile of powder or granules and the horizontal plane. A funnel was 
fixed at a height approximately of 2 cm over the platform. The loose 
powder was slowly passed along the wall of funnel, till the cone of 
the powder formed. Determine the angle of repose by measuring the 





Where, θ = angle of repose, h = height, r = radius. 
Post compression parameters of core and coated tablets 
The prepared tablets were evaluated for various parameters. 
Weight variation 
Twenty tablets were randomly selected and average weight was 
determined. Then individual tablets were weighed and percent 
deviation from the average was calculated. 
Thickness 
The thickness in millimeters (mm) was measured individually for 10 
pre weighed tablets by using screw gauge. The average thickness 
and standard deviation were reported.  
Hardness 
It was measured using a tablet hardness tester (Monsanto hardness 
tester). Three tablets from each formulation batch were tested 
randomly and the average reading noted [14]. 
Friability 
Friability of the tablets was determined using Roche Friabilator 
(Electrolab, India). This device consists of a plastic chamber that is 
set to revolve around 25 rpm for 4 min dropping the tablets at a 
distance of 6 inches with each revolution. Pre weighed sample (W0) 
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of 20 tablets was placed in the friabilator and were subjected to 100 
revolutions. Tablets were dusted using a soft muslin cloth and 





Where, W0 is weight of the tablets before the test and W is the 
weight of the tablets after test 
Disintegration time 
Disintegration time was measured using a disintegration apparatus. 
Randomly six tablets were selected from each batch for 
disintegration test. Disintegration test was performed in 900 ml 6.8 
pH phosphate buffer with SLS (0.3%) at 37±0.5 °C temperature and 
at the rate of 30±2 cycles/min. 
Assay 
Twenty tablets were randomly selected and average weight was 
calculated. Tablets were powdered in a glass mortar. Powder 
equivalent to 5 mg was weighed and dissolved in 100 ml of 6.8 pH 
phosphate buffer with SLS (0.3%) in volumetric flask. This 
C = K
dispersion was filtered and 1.2 ml of the above solutions were taken 
and diluted to 10 ml with distilled water. The absorbance of this 
solution was determined at 286 nm against the blank. The 
percentage assay was calculated from the standard curve. 
Dissolution study 
The release rate of lansoprazole was determined using USP 
dissolution testing apparatus-2 (paddle method). The dissolution 
medium was 0.1N HCl and 6.8 pH phosphate buffer with SLS (0.3%). 
For core tablets 900 ml of 6.8 pH phosphate buffer with SLS (0.3%) 
was used as dissolution media. For coated tablets, 500 ml of 
dissolution medium of 0.1N HCl was taken in dissolution apparatus 
for 120 min. Then 25 ml was withdrawn and leaving the remaining 
475 ml for the use in the buffer stage. Add 425 ml of 6.8 pH 
phosphate buffer with SLS (0.3%) into each bowl containing 475 ml 
of 0.1 N hydrochloric acid sample solution. Adjust PH 6.8 by using 
dilute orthophosphoric acid or dilute sodium hydroxide. The 
dissolution was performed at 37±0.5 °C temperature with 75 rpm. A 
sample (5 ml) of the solution was withdrawn from the dissolution 
apparatus hourly and the samples were replaced with fresh 
dissolution medium [15]. The samples were filtered and absorbance 
of these solutions was measured at about 306 nm, using acid stage 
media as blank and at 286 nm using buffer as blank using a UV 
spectrophotometer. The percentage drug release was plotted against 
time to determine the release profile. 
Analysis of drug release kinetics 
To analyze the in vitro release data various kinetic models were used 
to describe the release kinetics [14]. The zero order rate Eq. (1); first 











Where, C is the concentration of drug at time t, K
--------Eq. (4) 
0 is zero-order rate 
constant, t is time, C0 is the initial concentration of drug, K1 is first 
order constant, Q is the amount of drug at time t, KH is the constant 
reflecting the design variables of the system, Mt/M∞
Drug-excipient compatibility 
 is fraction of 
drug released at time t, K is the release rate constant incorporating 
structural and geometric characteristics of the tablet, and n is the 
release exponent. The n value is used to characterize different 
release mechanisms.  
Lansoprazole compatibility with excipients was studied by FTIR and 
DSC. The IR spectroscopy was obtained by a FTIR 
spectrophotometer (Shimadzu, Japan) using KBR pellets [16]. DSC 
analysis was performed using Q-1000 TA Instruments Perkin-Elmer 
pyris differential scanning calorimeter (DSC). The instrument was 
calibrated with indium standard. 3-5 mg samples were weighed and 
placed in a closed, hermetic sample pans with pin hole. 
Thermograms were obtained by heating the sample at a constant 
rate 10 °C/min. A dry purge of nitrogen gas (50 ml/min) was used 
for all runs. Samples were heated from 0 °C to 210.0 °C. The melting 
point, heat of fusion, appearance of any new peak and peak shape 
were noted [16].  
Surface morphology 
Surface Morphology and cross-sectional view of coated tablets were 
evaluated by SEM. The surface should be uniform and the core tablet 
should be completely surrounded by the coat. 
Stability 
The stability studies of prepared formulations were carried out at 
accelerated stability condition (40 °C±2°C/75%±5% RH) as per ICH 
guidelines over a period of 3 mo. The changes in their physical 
appearance, average weight of tablets, hardness, release profile and 
the drug content were observed.  
RESULTS AND DISCUSSION 
Lansoprazole core tablets were prepared according to formulations 
CT1-CT6. The amount of SSG is gradually increased from 1.5%-5.5% 
of tablet weight in CT1 to CT5, where as in CT6, SSG is not used. In 
the core tablet formulation PVP is added which is used as binder, 
magnesium stearate is used as lubricant and MCC is used as diluent. 
This powder mixture was dry blended and compressed in 4.76 mm 
punch to form 50 mg tablet. These formed tablets were further 
evaluated. 
The physical properties like bulk density, tapped density, 
compressibility index, Hausner’s ratio and angle of repose for 
lansoprazole and formulations CT1 to CT6 blend are shown in table 3. 
 
Table 3: Pre compression parameters of core tablets 
Formulation Bulk density (gm/cc) Tapped density (gm/cc) Compressibility index (%) Hausner's ratio Angle of repose 
Drug 0.40±0.23 0.58±0.32 31.03±0.24 1.43±0.1 39 °±0.29 
CT1 0.581±0.097 0.646±0.078 9.63±0.14 1.10±0.1 23 °±0.17 
CT2 0.584±0.103 0.649±0.063 10.02±0.23 1.11±0.2 23 °±0.30 
CT3 0.583±0.057 0.646±0.101 9.69±0.19 1.10±0.1 23 °±0.24 
CT4 0.563±0.068 0.646±0.073 12.84±0.28 1.14±0.1 22 °±0.11 
CT5 0.560±0.095 0.642±0.059 13.24±0.35 1.15±0.2 22 °±0.32 
CT6 0.589±0.104 0.648±0.092 9.1±0.16 1.10±0.1 23 °±0.29 
Values are expressed as mean±SD, n=3 
 
From table 3 it is seen that lansoprazole has poor flow property. But 
when mixed with excipients the flow property is excellent. From CT1-
CT3 and CT6 the flow property is excellent, because MCC increases the 
flow property. For CT4 and CT5 the flow property is good (from 
Hausner’s ratio inference), because when compared to CT1-CT3 and 
CT6, MCC amount is reduced. So, there is slight decrease in flow 
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property of mixture. As the angle of repose which indicates flowability 
and compressibility index which indicates compressibility is good, 
direct compression is used for formulation of tablets. 
The compressed tablets are evaluated for physico-chemical 
parameters such as hardness, thickness, friability, weight variation, 
assay and disintegration test. These are given in table 4. 
  
Table 4: Post compression parameters of core tablet 






Weight variation (%) Assay (%) Disintegration time (min) 
CT1 2.14±0.45 2.5±0.25 0.82±0.04 4.923±0.05 99.58±1.65 3.6±0.35 
CT2 2.23±0.01 2.7±0.02 0.86±0.06 3.912±0.05 99.67±0.08 2.0±0.28  
CT3 2.29±0.03 2.2±0.02 0.69±0.02 4.04±0.07 100.1±0.38 1.1±0.24 
CT4 2.32±0.04 2.4±0.04 0.67±0.07 3.98±0.06 99.56±0.11 0.45±0.17 
CT5 2.53±0.05 3.0±0.01 0.71±0.01 3.87±0.05 99.78±0.15 0.30±0.25 
CT6 2.26±0.04 2.7±0.02 0.76±0.04 3.92±0.02 100.78±0.87 6.1±0.23 
Values are expressed as mean±SD, n=3. 
 
The hardness test is one of the control parameter during the 
manufacturing of tablets. The recommended hardness for core tablet 
is 2-3 kg/cm2
Dissolution study of the core tablets was performed in 6.8pH 
phosphate buffer with 0.3% SLS. Formulations containing SSG (CT1 to 
CT5) released within 15 min, except CT6 which does not contain super 
disintegrant, released in 20 min. From fig. 1, we can observe that with 
increase in the SSG concentration the dissolution time is decreased. 
The core tablet CT2 which consists of optimum amount of SSG (2.5% 
i.e., 1.25 mg) is used to develop press coated tablets. As the objective is 
to overcome the acid instability and then immediate release of drug. 
. The hardness of core tablets from CT1-CT6 is found to 
be within limits. The thickness of tablets is related to tablet 
hardness. The thickness of all core tablets is found to be within 
limits. The average weight variation of tablets was found within 
limits of 5% (according to Indian Pharmacoepia). The average 
weight variation of core tablets CT1-CT6 was within 3-4% range 
which indicates that they are within limits. The friability value which 
is also affected by the hardness value of tablets should be in the 
range of 0.5-1% limits [17]. It was found that the friability of 
prepared core tablets is within standards. The assay of all core 
tablets was found to be within limits. The disintegration test is 
performed for all core tablets. From CT1-CT5 the amount of SSG is 
increased. The disintegration time is decreased based on amount of 
SSG. So, for CT5 the disintegration time is faster when compared to 
all other formulations i. e, CT1-CT4. In CT6 formulation SSG is not 




Fig. 1: Dissolution profile of core tablet (values are expressed as mean±SD, n=3) 
 
To the core tablet CT2, different polymers (ethyl cellulose, HPMC E15 
and HPMC K4M) were added according to table 2 and compressed into 
a tablet. The prepared press coated tablets were further evaluated for 
hardness, thickness, friability, weight variation and assay. The 
recommended hardness for tablet is 4-8 kg/cm2. From formulations 
F1-F13 the hardness was found to be within range 4-5 kg/cm2
Press-coated tablets were evaluated for drug release in 0.1NHCL and 
6.8 pH phosphate buffer with 0.3% SLS. From fig. 2, it is observed as 
ethyl cellulose is decreased gradually from F1-F6 drug release is 
increased and from F7-F13 (fig. 3) as ethyl cellulose is increased 
gradually drug release is decreased. 
which 
indicate that the hardness is within limits. The thickness of tablets is 
related to tablet hardness. The thickness of all tablets is found to be 
within limits. The average weight variation of tablets was found to be 
within range 2-4% which indicates that it is within limits. It was found 
that the friability of prepared tablets was within the range 0.6-0.8%. 
The assay of prepared tablets was also found within the limits with 
range 97-99%. 
Varying concentrations of ethyl cellulose incorporated controlled 
the drug release. This may be attributed due to decreased 
penetration of the solvent molecules in the presence of the 
hydrophobic polymer, leading to reduced diffusion of the drug from 
the matrix. Leuenberger et al. reported that, according to 
penetration theory, when a matrix is composed of a water-insoluble 
polymer, drug release occurs by dissolution of the active ingredients 
through capillaries composed of interconnecting drug particle 
clusters and the pore [18]. As drug release continues, the 
interconnecting clusters increase the pore network through which 
interior drug clusters can diffuse with more ethyl cellulose particles 
present, and the theory predicts that fewer clusters of soluble drug 
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substance are formed. Furthermore, the presence of finite drug 
clusters is more statistically possible. The resulting pore network 
becomes less extensive and more tortuous resulting in slower drug 
release. R. Enayatifard reported that, although incorporation of EC 
controlled drug release to some extent, the combination of this 
polymer with HPMC increased the release of the drug i.e.94% in 8 h 
in diltiazem tablet formulation. The reason might be that its large 
hydrophobic molecules imposed a discontinuity in the gel-structure 
leading to formation of a weaker barrier than the HPMC gel alone 
[14]. Pham AT et al. and Skoug et al. reported that the extent of 
polymer swelling and the hydration of the microstructure formed 
within the gel layer also vary with the degree of polymer interaction 
with hydrating media [19, 20]. Gangane P. S. et al. reported captopril 
release from press coated tablets depends on ratio of EC/HPMCK4M 
used [21]. Formulation F5 (10 mg EC, 90 mg HPMC E15) and F9 (25 
mg EC,75 mg HPMC K4M) were optimized based on limit given in 
United states pharmacopoeia (USP) i.e., USP limit-NMT 10% drug 
release in 0.1N HCl and NLT 75% in 6.8 pH buffer. 
The data obtained from dissolution studies of the entire 
formulations F1-F13 were fitted to various kinetic equations such as 
zero order, first order, Higuchi's model, Korsemeyer peppas. The 
results are shown in table 5. 
 
 
Fig. 2: Dissolution profile of F1-F6 (values are expressed as mean±SD, n=3) 
 
 
Fig. 3: Dissolution profile of F7-F13 (values are expressed as mean±SD, n=3) 
 
Table 5: Drug release kinetics 
Formulation code Zero order  First order  Higuchi  Korsemeyer-peppas Release mechanism  
R2 R  2 R  2 R  2 n    
F1  1  0.818  0.648  0.945  1.385  Super case 2  
F2  0.927  0.791  0.703  0.778  1.759  Super case 2  
F3  0.939  0.771  0.711  0.689  1.430  Super case 2  
F4  0.89  0.965  0.969  0.650  1.770  Super case 2  
F5  0.913  0.939  0.679  0.973  2.429  Super case 2  
F6  0.913  0.884  0.681  0.932  2.617  Super case 2  
F7  0.949  0.896  0.762  0.950  2.367  Super case 2  
F8  0.906 0.958 0.675 0.994 2.075  Super case 2  
F9  0.926 0.877 0.711 0.929 2.597 Super case 2  
F10  0.936 0.901  0.723  0.968  2.183  Super case 2  
F11  0.94  0.798  0.725  0.816  2.521  Super case 2  
F12  0.900  0.813  0.662  0.751  2.650  Super case 2  
F13  0.900  0.753  0.665  0.742  2.583  Super case 2  
 
From table 5, it was observed that the “n” value of 2.429 obtained for F5 
formulation, the drug release was found to follow super case 2 transport. 
This value indicates erosion mechanism. Also, the drug release 
mechanism was best explained by first order equation, as the plots 
showed the highest linearity (r2 = 0.939), followed by korsemeyer 
peppas equation (r2= 0.973). As the drug release was best fitted in first 
Prasanthi et al. 
Int J App Pharm, Vol 11, Issue 4, 2019, 49-56 
 
54 
order kinetics, it indicated that the rate of drug release is concentration 
dependent. For optimized formulation F9, “n” value was found to be 
2.367. The drug release was found to follow super case 2 transport. This 
value indicates erosion mechanism. Also, the drug release mechanism 
was best explained by zero order equation, as the plots showed the 
highest linearity (r2 =0.926), followed by korsemeyer peppas equation 
(r2
The optimized formulations were further studied for drug excipient 
compatibility, surface morphology and stability. 
= 0.929). As the drug release was best fitted in zero order kinetics, it 
indicated that the rate of drug release is concentration independent. 
From fig. 4 FTIR studies it was observed that the characteristic 
peaks at 1170(C-O-C bending), 3200 (N-H stretching), 1268 (C=N 
stretching), 1600(C=O stretching), 2988, 2940, 2884 (C-H 
stretching) are present in both the pure drug and formulation, 
indicating no chemical interaction between drug and excipients. 
 
 
Fig. 4: FTIR peaks of drug, formulation F5 and formulation F9 
 
 
Fig. 5: DSC peaks of drug, formulation F5 and formulation F9 
 
Thermal behavior of pure lansoprazole, formulation F5 and F9 
physical mixture are depicted in fig. 5. The pure lansoprazole 
showed melting endothermic peak at 176.99 °C, in formulation F5 
peak 177.84 °C and formulation F9 peak at 178.91 °C. These minor 
changes may not necessarily indicate potential incompatibility. 
The effect of coating on the morphology of the core tablet was 
observed using SEM. The main objective of scanning electron 
microscopy is to study the different coating layers on core tablet. 
Obtained SEM photographs of tablets coated with ethyl cellulose and 
HPMC E15 i.e. F5 and tablets coated with ethyl cellulose and HPMC 
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K4M i.e. F9 are shown in fig. 6. From this we can observe that coating is uniform for both the optimized formulations. 
 
 
Fig. 6: SEM of formulation F5 and F9 
 
Stability of a drug in a dosage form at different environmental 
conditions is important as it determines the expiry date of that 
particular formulation. Among the 13 formulations optimized 
formulations F5 and F9 were selected for stability studies. The 
stability studies of optimized formulation F5 and F9 (table 6) was 
carried out at 40 °C±2°C/75%±5% RH as per ICH guidelines over a 
period of 3 mo. There is no significant change in their physical 
appearance, average weight of tablets and hardness. The release 
profile and the drug content also did not show any significant 
changes indicating that there were no changes in the physical as 
well as chemical characteristics of the formulation [22]. Hence, it 
can be concluded from the results that the developed tablets were 
stable and retain their pharmaceutical properties over a period of 
3 mo. 
  
Table 6: Stability studies of formulation F5 andF9 
Parameters  formulation F5 formulation F9 
Initial 1st 2 month  nd 3 month  rd Initial  month  1st 2 month  nd 3 month  rd month  
Physical appearance  white white  white  white  white white  white  white  
Weight variation (%) 4.06±0.07  4.06±0.07  4.06±0.07  4.06±0.07  3.91±0.05  3.91±0.05  4.02±0.09  4.08±0.07  
Hardness (kg/cm2 4.7±0.02  ) 4.7±0.02  4.7±0.02  4.7±0.02  4.5±0.02  4.5±0.02  4.5±0.02  4.5±0.02  
Drug content (%)  98.14±0.22  98.14±0.22  97.32±0.22  97.21±0.22  97.8±0.51  97.8±0.51  97.8±0.87  97.21±0.23 
Friability (%) 0.86±0.06 0.86±0.06 0.86±0.06  0.86±0.06  0.69±0.02 0.69±0.02 0.69±0.02 0.69±0.02 
Invitro release (%) in 8Hrs 98.53±0.05  98.53±0.07  96.38±0.04  96.11±0.06  102.33±0.11  102.33±0.03  101.99±0.14  101.84±0.12  
Values are expressed as mean±SD, n=3. 
 
CONCLUSION 
Lansoprazole is an acid liable drug which degrades at acidic pH of 
stomach. In order to delay the release in the stomach and promote the 
drug release in the intestine, enteric coating of the drug was 
attempted. An enteric coated delayed release formulation was 
successfully formulated by press coating technique. Among the 
various formulations F5 containing ethyl cellulose: HPMC E15 (10:90) 
and F9 containing ethyl cellulose: HPMC K4M (25:75) were optimized 
based on the better drug release within 8 h, according to USP limit-
NMT 10% in 0.1N HCl and NLT 75% in 6.8 pH buffer. These both 
formulations gave delayed release for 8 h. FTIR characterization and 
DSC studies of drug with excipients indicated that there was no drug-
polymer interaction. SEM photographs of tablets showed that core 
tablet is uniformly coated by coating layer by press coating. Stability 
studies showed that the formulations were stable.  
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